Clinical trials: Endometrial Intraepithelial Neoplasia

Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma

Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer

• Withdrawn
• Age: 18 to 44 years
• Phase 2
• Medical device

This randomized phase II trial studies how well megestrol acetate or levonorgestrel-releasing intrauterine system works in treating patients with atypical endometrial hyperplasia or endometrial cancer.

Conditions

Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IA Endometrial Carcinoma

Trial name

NCT01943058

Testing

megestrol acetate, levonorgestrel-releasing intrauterine system, laboratory biomarker analysis

Sponsor

University of Southern California